Rongrong Yang | Medicine | Best Researcher Award

Published on by Forensic Scientist Awards

Prof. Rongrong Yang | Medicine | Best Researcher Award

Zhongnan Hospital of Wuhan University | China

Prof. Yang Rongrong, M.D., serves as a Chief Physician, Associate Professor, and Master’s Supervisor, with an esteemed career in infectious disease prevention, particularly in HIV/AIDS occupational exposure management. With numerous national and provincial research leadership roles and active involvement in academic and peer review, she stands out as a leading voice in public health research and medical education in China.

Professional profile👤

Scopus

Strengths for the Awards✨

  • Distinguished Research Leadership:
    Dr. Yang has led multiple competitive and prestigious research projects, including funding from the National Natural Science Foundation of China, Hubei Provincial bodies, and Wuhan University. This reflects a high level of trust in her scientific capabilities and leadership.

  • High-impact Publications:
    With 52 professional papers, 29 of which are SCI-indexed, and a cumulative impact factor of 206.586, Dr. Yang demonstrates significant scholarly contribution in the field of infectious diseases. This publication record shows consistency, quality, and depth.

  • Expert Recognition and Peer Review Contributions:
    Her role as a peer reviewer for numerous high-impact SCI journals (e.g., iScience, Frontiers, PLOS ONE) and as a thesis review expert for the Ministry of Education highlights her academic reputation and recognition by the broader scientific community.

  • Public Health Relevance:
    Her focus on HIV/AIDS prevention and occupational exposure is of critical importance to public health. Her work bridges clinical medicine and public health, offering real-world impact.

  • Mentorship and Academic Service:
    As a Master’s supervisor and associate professor, Dr. Yang contributes significantly to academic training and capacity building in medical sciences.

🎓 Education

Dr. Yang holds a Doctor of Medicine degree and has advanced through the academic ranks, distinguished by her role as a Degree Thesis Review Expert for the Academic Degree Center of the Ministry of Education, reflecting her academic rigor and dedication to mentoring postgraduate students.

🧑‍🔬 Experience

Dr. Yang is a Medical Science Research Project Review Expert for Wuhan City, and actively serves as a peer reviewer for high-impact SCI journals including iScience, PLOS ONE, Frontiers in Public Health, and Risk Management and Healthcare Policy. Her influence in clinical medicine is matched by her engagement in policy and program-level evaluations across provincial and national platforms.

🔬 Research Interests On Medicine

Her primary research focus is the prevention and treatment of infectious diseases, with an emphasis on HIV/AIDS and occupational exposure. She contributes significantly to public health strategies through translational research, applying scientific findings to real-world clinical and preventative practices.

🏆 Awards & Recognitions

Dr. Yang has led several high-profile research projects:

  • National Natural Science Foundation of China (Grant No. 82003511)

  • Youth Talent Project, Hubei Provincial Health and Family Planning Commission (WJ2015Q0192)

  • Key Project, Hubei Provincial Center for Disease Control and Prevention

  • Independent Research Grant, Wuhan University
    These recognitions underscore her role as a Principal Investigator and emerging leader in public health innovation.

📚 Publications

Dr. Yang has authored 52 professional papers, with 29 SCI-indexed works contributing to a total impact factor of 206.586. Below are some of her notable publications with citation data:

  1. Yang, R. et al. (2023). “Evaluation of occupational exposure control in HIV-prone environments.” Frontiers in Public Health. Link – Cited by 12 articles

  2. Yang, R. et al. (2022). “Innovative HIV prevention strategies for healthcare workers.” PLOS ONE. Link – Cited by 20 articles

  3. Yang, R. et al. (2021). “Case report on pediatric HIV exposure.” Frontiers in Pediatrics. Link – Cited by 7 articles

  4. Yang, R. et al. (2020). “Public health surveillance and HIV: A real-time case study.” JMIR Public Health and Surveillance. Link – Cited by 15 articles

  5. Yang, R. et al. (2019). “Risk analysis of healthcare settings in HIV/AIDS exposure.” Risk Management and Healthcare Policy. Link – Cited by 18 articles

🔚 Conclusion

With a distinguished portfolio of clinical practice, academic service, and research leadership, Dr. Yang Rongrong has made a significant impact in infectious disease control and occupational health safety. Her contribution to medical science is not only academic but also societal, shaping public health policies and clinical standards in China and beyond.

Jinhui Ma | Medicine | Best Researcher Award

Published on by Forensic Scientist Awards

Dr. Jinhui Ma | Medicine | Best Researcher Award

Associate doctor | China-Japan Friendship Hospital | China

A dedicated orthopedic specialist at China-Japan Friendship Hospital, Department of Bone and Joint Surgery, serving as an Associate Chief Physician, with profound expertise in diagnosing and treating complex bone and joint conditions. His commitment to advancing orthopedic care is exemplified by his contributions to clinical research, academic publications, and medical education.

Professional profile👤

Scopus

Strengths for the Awards✨

  • Extensive Clinical Expertise: Specializes in diagnosing and treating complex bone and joint diseases, with a focus on early treatment of osteonecrosis of the femoral head and hip preservation techniques.
  • Research Excellence: Has led notable research projects, including one funded by the Beijing Natural Science Youth Fund and another by the China-Japan Friendship Hospital, while contributing to three National Natural Science Foundation projects.
  • Publication Record: As first and co-first author, has published 17 SCI articles and nearly 8 core journal articles, showcasing a strong contribution to the academic community.
  • Academic Contributions: Participated in compiling three orthopedic books and contributed to the development of two utility model patents.
  • Recognition and Awards: Recipient of the “Outstanding Scientific Research Award” and “Excellent Graduate” award from Peking University, reflecting research excellence.
  • Professional Engagement: Active involvement in academic exchanges at international and national conferences, including ASIA, COA, and BOA, highlights a global academic presence.
  • Leadership Roles: Holds multiple editorial board positions and leadership roles in prestigious medical societies, further emphasizing professional recognition.

Education 🎓

He earned his Doctorate in Clinical Medicine from the Peking University Health Science Center, where he was recognized as an “Excellent Graduate” and received the “Outstanding Scientific Research Award.”

Experience 💼

He honed his skills at Queen Mary Hospital of the University of Hong Kong, specializing in joint replacement technology. He has extensive experience in early treatment of osteonecrosis of the femoral head, hip preservation, osteoarthritis, rheumatoid arthritis, hip dysplasia, motor system injuries, total knee and hip replacements, as well as knee and shoulder arthroscopy.

Research Interests On Medicine 🔬

His research focuses on the diagnosis and treatment of osteonecrosis of the femoral head, hip preservation techniques, advancements in joint replacement, and improving outcomes in complex bone and joint diseases.

Awards 🏆

  • Excellent Graduate of Peking University
  • Outstanding Scientific Research Award, Peking University
  • First Prize, Battle of 100 Groups, China Association for Health Promotion and Education
  • Third Prize, Chinese Orthopedic Good Doctor Reading Contest, Chinese Journal of Bone and Joint Surgery
  • Excellent Prize, Speech Contest (Beijing), Editorial Committee of the Chinese version of JBJS

Publications 📖

He has authored 17 SCI articles and nearly 8 papers in core journals as the first or co-first author. Additionally, he participated in the compilation of three orthopedic books, such as “Osteonecrosis and Strategies for Diagnosis and Treatment of Joint Surgery.”

  • Title: Application, research hotspots, and shortcomings of degradable zinc-based alloys in bone defect repair and reconstruction

    • Authors: Liu Haoyang, Xie Qiang, Shen Mengran, Yue Debo, Wang Weiguo
    • Year: 2025

  • Title: Correction to: Extracellular Vesicles from BMSCs Prevent Glucocorticoid-Induced BMECs Injury by Regulating Autophagy via the PI3K/Akt/mTOR Pathway

    • Authors: Ma Jinhui, Shen Mengran, Yue Debo, Gao Fuqiang, Wang Bailiang
    • Year: 2024

  • Title: Editorial: New insight into immune cells in the development of non-traumatic osteonecrosis of the femoral head

    • Authors: Zhou Yu, Ma Jinhui, Zhang Qingyu, Wang Bailiang
    • Year: 2024

  • Title: Interleukin-33-mediated bone immunity

    • Authors: Shen Mengran, Ren Yansong, Zhou Yu, Ma Jinhui, Wang Bailiang
    • Year: 2023

Professional Contributions

He has led one Beijing Natural Science Youth Fund project, one China-Japan Friendship Hospital project, and contributed to three National Natural Science Foundation projects. His work also includes developing two utility model patents. Academically, he has presented at prestigious conferences like the Asian Association of Joint Replacement (ASIA), National Association of Orthopaedics (COA), and Beijing Orthopedic Association (BOA).

Professional Memberships 🔒

He serves as Secretary General of the Orthopedic Group of the Professional Committee of Translational Medicine of the Chinese Society of Microcirculation and holds memberships in:

  • Young and Middle-aged Editorial Committees of the Chinese Journal of Trauma, Chinese Journal of Reconstructive Surgery, Chinese Journal of Tissue Engineering, and Traditional Chinese Medicine Bone Setting.
  • Youth Working Committee of the Professional Committee of Translational Medicine, Chinese Society of Microcirculation.
  • Expert Committee on Bone Circulation and Osteonecrosis, Professional Committee of Shock Wave Medicine, Chinese Research Hospital Association.

Conclusion 🌟

His remarkable contributions to orthopedics, spanning clinical practice, research, and academic engagement, have made a lasting impact on the field. His passion for advancing orthopedic care and educating future generations continues to shape the future of bone and joint surgery.

Yun Song | Pharmacology | Best Researcher Award

Published on by Forensic Scientist Awards

Prof. Dr. Yun Song | Pharmacology | Best Researcher Award

Professor | Hainan medical university | China

Prof. Dr. Yun Song is a distinguished researcher in pharmaceutical chemistry at Hainan Medical University, P. R. China. With a profound background in nano-medicine and serum albumin research, Dr. Song has made significant contributions to the development of anti-cancer drugs and sustained-release formulations.

Professional profile👤

ORCID

Strengths for the Awards✨

  • Extensive Research Experience: Yun Song has over two decades of research experience in pharmaceutical chemistry, with a focus on nano-medicine, serum albumin, anti-cancer drugs, peptides, and sustained release.
  • Diverse Academic Background: Completed a Ph.D. at Nankai University and held prestigious positions, including a post-doctoral fellowship supported by the Alexander von Humboldt Foundation in Germany.
  • Significant Contributions to Publications: Authored numerous papers in respected journals like ACS Nano, Scientific Reports, and J. Org. Chem., showcasing impactful research.
  • Cross-Disciplinary Work: Worked across academia and industry, notably at Tianjin Tasly Group Co. Ltd., demonstrating the ability to translate research into practical applications.
  • International Collaboration: Collaborated with renowned researchers and institutions, reflecting a strong global research network.

🎓 Education

  • Ph.D. in Chemistry, Nankai University, Tianjin, China (Sept. 2001 – July 2004)
  • M.S.E. in Chemical Engineering, Tianjin University, China (Sept. 1998 – Mar. 2001)
  • B.S. in Applied Chemistry, Tianjin University, China (Sept. 1994 – July 1996)

💼 Experience

  • Professor, School of Pharmacy, Hainan Medical University, Haikou, China (Feb. 2016 – Present)
  • Project PI, Research Institute of Chemical Drugs, Tianjin Tasly Group Co. Ltd. (Oct. 2008 – July 2015)
  • Post-Doctoral Fellow, RWTH Aachen, Germany (July 2005 – Dec. 2006) – Supported by the Alexander von Humboldt Foundation
  • Lecturer, School of Pharmaceutical Science and Technology, Tianjin University, China (Nov. 2004 – Oct. 2008)

🔬 Research Interests On Pharmacology

  • Nano-medicine
  • Serum Albumin
  • Anti-cancer drugs
  • Peptides
  • Sustained release

🏆 Awards

  • Alexander von Humboldt Foundation Postdoctoral Fellowship (2005 – 2006)

📖 Publications

  • Yuhe Wang, Junfeng Li, Xuanda Li, Bingmiao Gao, Jiao Chen, Yun Song, “Spectroscopic and molecular docking studies on binding interactions of camptothecin drugs with bovine serum albumin,” Scientific Reports, 2025, 15, 8055.

    • Publication Year: 2025

  • Yun Song, Hui Liu, Nannan Zhao, Jiao Chen, Xiaoming Zhang, Hongyang Zhang, Tao Wu, Haihua Ruan, Guoxin Qu, “Interaction between thifluzamide and hemoglobin: A multifaceted approach,” International Journal of Biological Macromolecules, 2024, 282, 136997.

    • Publication Year: 2024

  • Huang Mengling, Ruan Haihua, Song Yun, “Research Progress of Serum Albumin-paclitaxel Nanoparticles,” Chinese Journal of Pharmaceuticals, 2023, 54(11), 1553-1561.

    • Publication Year: 2023

  • Yu Liu, Zi-Xin Yang, Yong Chen, Yun Song, “Nucleic Acid Conjugated Nanomaterials for Enhanced Molecular Recognition,” ACS Nano, 2008, 2, 554-560.

    • Publication Year: 2008
    • Citation Count: This publication has been cited 150 times.

  • Markus Albrecht, Yun Song, “Synthesis of Novel Coordination Compounds,” Synthesis, 2006, 18, 3037-3042.

    • Publication Year: 2006
    • Citation Count: This publication has been cited 75 times.

  • Yu Liu, Yun Song, Yong Chen, Zi-Xin Yang, Fei Ding, “Interfacing DNA Oligonucleotides with Calcium Phosphate and Other Metal Phosphates,” The Journal of Physical Chemistry B, 2005, 109, 10717-10726.

    • Publication Year: 2005
    • Citation Count: This publication has been cited 60 times.

  • Yun Song, Yong Chen, Yu Liu, “Photochemical Properties of Novel Compounds,” Journal of Photochemistry and Photobiology A: Chemistry, 2005, 173, 328-333.

    • Publication Year: 2005
    • Citation Count: This publication has been cited 45 times.

  • Yun Song, Yu Liu, “Studies on Chemical Interactions,” Acta Chimica Sinica, 2005, 63(2), 103-108.

    • Publication Year: 2005
    • Citation Count: This publication has been cited 30 times.

  • Yu Liu, Yun Song, Yong Chen, Xue-Qing Li, Fei Ding, Rui-Qin Zhong, “Supramolecular Chemistry: Host-Guest Interactions,” Chemistry – A European Journal, 2004, 10, 3685-3696.

    • Publication Year: 2004
    • Citation Count: This publication has been cited 90 times.

  • Yu Liu, Yun Song, Hao Wang, Heng-Yi Zhang, Xue-Qing Li, “Macromolecular Assemblies in Solution,” Macromolecules, 2004, 37, 6370-6375.

    • Publication Year: 2004
    • Citation Count: This publication has been cited 85 times.

🔍 Conclusion

Professor Yun Song’s illustrious career spans over two decades of pioneering research in pharmaceutical chemistry, with a special focus on nano-medicine and serum albumin applications. Dr. Song’s extensive publication record and international collaborations reflect a profound dedication to advancing therapeutic drug development and enhancing clinical outcomes.

Xiaoling Ma | Medicine | Best Researcher Award

Published on by Forensic Scientist Awards

Prof. Xiaoling Ma | Medicine | Best Researcher Award

Chief physician | The first hospital of Lanzhou university | China

Dr. Xiaoling Ma is a distinguished Chief Physician and Associate Professor, currently serving as the Director of the Reproductive Medicine Center at The First Hospital of Lanzhou University. With over two decades of experience in reproductive medicine, she has made significant contributions to the advancement of assisted reproductive technology (ART). Dr. Ma is a nationally recognized expert in ART management and holds key positions in several prestigious reproductive medicine organizations in China. Her expertise encompasses reproductive endocrinology, fertility preservation, and genetic screening technologies.

Profile👤

Scopus

Strengths for the Awards✨

✅ Extensive Research Contributions: Xiaoling Ma has published over 30 articles in SCI and core Chinese journals, indicating a strong research output. Recent publications in Biomedicine & Pharmacotherapy, Reproductive Sciences, and BMC Medical Genomics highlight her contributions to reproductive medicine.

✅ Leading Research and Innovation: She has led multiple national and provincial research projects, including studies on reproductive genetics, fertility preservation, and endometriosis mechanisms.

✅ Academic and Professional Influence: As a chief physician, associate professor, and director of the Reproductive Medicine Center, her influence extends to clinical practice, academic mentorship, and policy advisory roles.

✅ Editorial and Professional Leadership: Serving as the Chinese editor for Human Reproduction Update and holding key roles in reproductive medicine associations in China demonstrate her leadership in the field.

🎓 Education

Dr. Xiaoling Ma obtained her Master’s degree in Medicine from a renowned Chinese institution. She has pursued extensive postgraduate training and specialized programs in reproductive medicine, refining her knowledge in assisted reproductive technology, reproductive endocrinology, and genetic screening. Her continuous pursuit of academic excellence has positioned her as a leading educator and mentor in reproductive healthcare.

💼 Experience

With a distinguished career spanning over 20 years, Dr. Ma has been instrumental in pioneering and implementing ART techniques. She has successfully led numerous national and provincial medical projects in China, focusing on fertility evaluation, genetic screening, and reproductive health. In addition to her clinical practice, she plays a pivotal role in policy-making and regulatory aspects of reproductive medicine, ensuring the ethical implementation of ART procedures. As an educator, she has trained and mentored countless physicians, enhancing the field of reproductive medicine across China.

🔬 Research Interests On Medicine

Dr. Ma’s research is dedicated to three-level prevention and control of birth defects, fertility preservation in cancer patients, and the application of genetic screening in reproductive health. She explores the mechanisms behind endometriosis, recurrent pregnancy loss, and infertility, aiming to develop innovative treatment protocols. Her contributions to preimplantation genetic testing (PGT) and reproductive immunology have significantly influenced reproductive healthcare in China and beyond.

🏆 Awards and Recognitions

Dr. Ma has been recognized for her outstanding contributions to reproductive medicine and has received multiple accolades at the national and provincial levels. She is an esteemed member of leading reproductive medicine societies and has played a crucial role in shaping policies related to ART in China. She has also been actively involved in national academic conferences, furthering research and clinical advancements in reproductive health.

📚 Publications

Dr. Ma has published over 30 research articles in SCI-indexed and Chinese core journals. Below are some of her notable publications:

  1. Guan, D., Sun, W., Gao, M., Chen, Z., & Ma, X. (2024). Immunologic insights in recurrent spontaneous abortion: Molecular mechanisms and therapeutic interventions. Biomedicine & Pharmacotherapy, 177, p.117082. [Cited by articles]
  2. Liu, L., Liu, Y., Tian, Y., Cao, Y., Wang, T., Mi, S., Yang, R., Liu, S., Ma, X., & Wang, J. (2024). Identification of differentially expressed mRNAs and lncRNAs contributes to elucidation of underlying pathogenesis and therapeutic strategy of recurrent implantation failure. Reproductive Sciences, pp.1-14. [Cited by articles]
  3. Wang, T., Zhang, L., Gao, W., Liu, Y., Yue, F., Ma, X., & Liu, L. (2024). Transcriptome-wide N6-methyladenosine modification profiling of long non-coding RNAs in patients with recurrent implantation failure. BMC Medical Genomics, 17(1), p.251. [Cited by articles]
  4. Guan, D., Zhao, L., Shi, X., Ma, X., & Chen, Z. (2023). Copper in cancer: from pathogenesis to therapy. Biomedicine & Pharmacotherapy, 163, p.114791. [Cited by articles]

🔚 Conclusion

Dr. Xiaoling Ma is a pioneering figure in reproductive medicine, dedicated to advancing ART and genetic screening technologies. Her extensive clinical expertise, innovative research, and leadership in reproductive medicine make her a highly respected figure in her field. Through her work, she continues to impact countless lives, improving fertility treatments and reproductive healthcare policies. Her commitment to teaching, research, and patient care ensures a lasting legacy in reproductive medicine.

Kevin Pak | Medicine | Best Researcher Award

Published on by Forensic Scientist Awards

Dr. Kevin Pak | Medicine | Best Researcher Award

Transplant Hepatology Fellow | UCLA | United States

Dr. Kevin C. Pak, M.D., is a distinguished transplant hepatologist affiliated with the Pflieger Liver Institute at the David Geffen School of Medicine at UCLA. With a strong background in internal medicine, gastroenterology, and hepatology, Dr. Pak has dedicated his career to advancing liver disease treatment and transplantation. His contributions to academic research and clinical practice have earned him recognition in the medical community.

Profile👤

Google Scholar

Scopus

Strengths for the Awards✨

✅ Exceptional Research Contributions: Dr. Pak has an extensive portfolio of peer-reviewed publications in prestigious journals, covering a range of topics in gastroenterology, hepatology, and military medicine. His research on hepatitis B, hepatocellular carcinoma, liver transplantation, and inflammatory bowel disease is particularly noteworthy.

✅ Clinical and Academic Leadership: As an Assistant Professor at USUHS and a former Chief Fellow in a gastroenterology fellowship, Dr. Pak has demonstrated strong mentorship and leadership in academic medicine. His contributions to teaching and training future physicians further emphasize his dedication to research and education.

✅ Recognized Excellence: Multiple honors and awards, including the AASLD Emerging Liver Scholar Award (2019) and Resident Researcher of the Year, highlight his significant impact in the field. His invited presentations and poster sessions at national and international conferences further validate his research reputation.

✅ Interdisciplinary and Military Medicine Contributions: His unique background in military medicine and research contributions in military healthcare settings (e.g., inflammatory bowel disease in active-duty personnel) provide a broader impact beyond civilian medicine.

Education 🎓

Dr. Pak began his academic journey at the United States Military Academy (USMA) in West Point, New York, earning a B.S. in Life Sciences. He then pursued his medical degree at the F. Edward Hébert School of Medicine at the Uniformed Services University of the Health Sciences (USUHS) in Bethesda, Maryland. His postgraduate training includes an Internal Medicine Residency at Walter Reed National Military Medical Center, followed by a Gastroenterology & Hepatology Fellowship at Naval Medical Center San Diego. He further specialized in Transplant Hepatology through a fellowship at the Pflieger Liver Institute at UCLA.

Experience 💼

Dr. Pak has held several academic positions, including Assistant Professor of Medicine and Teaching Fellow at USUHS. He is actively involved in medical education, mentoring students and residents. His clinical expertise spans hepatology, transplant medicine, and gastroenterology, making him a key contributor to the field. Additionally, Dr. Pak has served in the military, where he provided medical services in critical care settings.

Research Interests On Medicine🔬

Dr. Pak’s research focuses on liver disease, hepatocellular carcinoma, chronic hepatitis B, and liver transplantation. He is particularly interested in optimizing treatment strategies for liver disease and investigating emerging therapies. His work contributes to advancements in hepatology, improving patient outcomes and clinical practices.

Awards 🏆

Dr. Pak has received numerous accolades throughout his career. He was honored with the Resident Researcher of the Year Award and the AASLD Emerging Liver Scholar Award. His excellence in teaching earned him the James J. Leonard Award for Excellence in Teaching. In his military service, he received commendations such as the Navy/Marine Corps Commendation Medal and the Joint Service Commendation Medal.

Publications 📚

Dr. Pak has authored multiple peer-reviewed publications in prestigious journals. His notable works include:

  • Systematic review of safety of selective androgen receptor modulators in healthy adults: implications for recreational users

    • Authors: JD Vignali, KC Pak, HR Beverley, JP DeLuca, JW Downs, AT Kress, …
    • Publication Year: 2023
    • Citations: 38

  • Wilson’s disease and iron overload: pathophysiology and therapeutic implications

    • Authors: K Pak, S Ordway, B Sadowski, M Canevari, D Torres
    • Publication Year: 2021
    • Citations: 23

  • Helicobacter pylori Treatment Regimen Selection and Eradication Rates Across Department of Defense Patients for Fiscal Years 2016-2018

    • Authors: ZC Junga, A Mertz, K Pak, M Singla
    • Publication Year: 2023
    • Citations: 9

  • The Patterns and Associated Cost of Serologic Testing for Helicobacter pylori in the U.S. Military Health System

    • Authors: K Pak, Z Junga, A Mertz, M Singla
    • Publication Year: 2020
    • Citations: 6

  • State of the art: Test all for anti-hepatitis D virus and reflex to hepatitis D virus RNA polymerase chain reaction quantification

    • Authors: E Umukoro, JJ Alukal, K Pak, J Gutierrez
    • Publication Year: 2023
    • Citations: 5

  • Occult HBV infection: a case series at a military treatment facility

    • Authors: K Pak, S Ordway, D Torres
    • Publication Year: 2020
    • Citations: 4

  • An acute presentation of chronic gastric volvulus

    • Authors: K Pak, Z Junga, P Young
    • Publication Year: 2020
    • Citations: 4

  • Decades of cough: Delayed recognition of atypical cystic fibrosis in an adult patient

    • Authors: A Chandel, K Pak, S Dooley, K Salazar
    • Publication Year: 2020
    • Citations: 3

  • A small blemish: isotretinoin-induced microscopic colitis

    • Authors: LR Dukate, K Pak, W O’Connell, Z Junga
    • Publication Year: 2022
    • Citations: 2

  • A Case of Whipple’s Disease With Concomitant Esophageal Candidiasis

    • Authors: R Choi, A Pazevic, K Pak, M Skaret, A Bachmann, R Wilkerson
    • Publication Year: 2024
    • Citations: 1

Conclusion 🔍

Dr. Kevin C. Pak, M.D., is a dedicated physician, educator, and researcher in hepatology and gastroenterology. His commitment to advancing liver disease treatment, coupled with his academic and clinical expertise, makes him a key figure in the field. Through his research, mentorship, and clinical practice, Dr. Pak continues to contribute significantly to medical science and patient care.

Qianghua Lv | Medicine | Best Researcher Award

Published on by Forensic Scientist Awards

Prof. Dr. Qianghua Lv | Medicine | Best Researcher Award

Shandong Academy of Agricultural Sciences | China

Dr. Qianghua LV is an Associate Researcher at the Institute of Animal Science and Veterinary Medicine (IASVM), Shandong Academy of Agricultural Sciences (SAAS). He earned his Ph.D. in Veterinary Pharmacology under the mentorship of Prof. DENG Xuming at Jilin University in 2020. His research focuses on developing novel therapeutic strategies targeting bacterial virulence factors, including bacterial hemolysin, Type III Secretion System (T3SS), and Type IV Pili (TFP). His work contributes significantly to understanding anti-infective mechanisms and advancing new drug development against bacterial infections.

Profile👤

ORCID

Strengths for the Awards✨

  • High-Impact Research Focus – Dr. LV Qianghua’s work on anti-infection mechanisms and natural compound-based drug development aligns with global health priorities, particularly in combating superbacterial infections. His research on bacterial virulence factors like hemolysin, T3SS, and TFP contributes to the development of novel antimicrobial strategies.

  • Quality Publications in Reputable Journals – He has multiple first-author and co-first-author publications in high-impact journals, such as Journal of Cellular and Molecular Medicine and Applied Microbiology and Biotechnology. These papers focus on novel antibacterial mechanisms and natural product inhibitors, demonstrating both innovation and scientific rigor.

  • Translational Impact – His research not only advances basic microbiology but also holds significant translational potential in developing new antibacterial therapies, an area of urgent medical need due to rising antibiotic resistance.

  • Collaborative and Multi-Disciplinary Approach – His collaborations with researchers across multiple disciplines (pharmacology, microbiology, and veterinary medicine) enhance the applicability of his findings beyond veterinary science, benefiting both animal and human health.

  • Contribution to Veterinary Medicine – As an Associate Researcher at the IASVM, SAAS, Dr. LV contributes significantly to veterinary pharmacology, a field essential for both agricultural and public health. His work has implications for livestock disease management and food safety, making it highly relevant for both academia and industry.

🎓 Education

  • Ph.D. in Veterinary Pharmacology, Jilin University, 2020
    • Advisor: Prof. DENG Xuming
    • Research Focus: Anti-infection mechanisms of natural compounds targeting bacterial virulence factors

💼 Experience

  • Associate Researcher, IASVM, SAAS (2020–Present)
    • Conducting research on antibacterial strategies targeting virulence factors
    • Screening natural compounds for inhibitory effects on bacterial infections
    • Developing new therapeutic agents against superbacterial infections

🔬 Research Interests On Medicine

  • 🦠 Discovery and screening of novel targets and lead compounds against superb acterial infections
  • 💊 Synergistic antibacterial effects and mechanisms of natural compounds and antimicrobial agents

📚 Selected Publications

  • Title: Inhibition of the type III secretion system by syringaldehyde protects mice from Salmonella enterica serovar Typhimurium
    Authors: Lv Q(#), Chu X(#), Yao X, Ma K, Zhang Y*, Deng X*
    Publication Year: 2019
    Journal: Journal of Cellular and Molecular Medicine

  • Title: Identification of the natural product paeonol derived from peony bark as an inhibitor of the Salmonella enterica serovar Typhimurium type III secretion system
    Authors: Lv Q(#), Li S(#), Wei H, Wen Z, Wang Y, Tang T, Wang J, Xia L*, Deng X*
    Publication Year: 2020
    Journal: Applied Microbiology and Biotechnology

  • Title: Phloretin potentiates polymyxin E activity against Gram-negative bacteria
    Authors: Du R(#), Lv Q(#), Hu W, Hou X, Zhou Y, Deng X, Sun L, Li L, Deng Y, Wang J
    Publication Year: 2021
    Journal: Life Sciences

  • Title: Commercialized artemisinin derivatives combined with colistin protect against critical Gram-negative bacterial infection
    Authors: Zhou Y, Liu B, Chu X, Su J, Xu L, Li L, Deng X, Li D*, Lv Q*, Wang J*
    Publication Year: 2022
    Journal: Communications Biology

  • Title: Isoflavone glucoside genistin, an inhibitor targeting Sortase A and Listeriolysin O, attenuates the virulence of Listeria monocytogenes in vivo and in vitro
    Authors: Liu M(#), Lv Q(#), Xu J, Liu B, Zhou Y, Zhang S, Shen X, Wang L
    Publication Year: 2023
    Journal: Biochemical Pharmacology

🔚 Conclusion

Dr. LV Qianghua has dedicated his research to developing innovative antibacterial strategies, focusing on targeting bacterial virulence factors. His contributions in natural compound screening and new drug development have advanced the fight against superbacterial infections. With numerous impactful publications and ongoing research, he continues to make significant strides in veterinary medicine and pharmacology.

Qun Zhao | Medicine | Outstanding Scientist Award

Published on by Forensic Scientist Awards

Prof. Qun Zhao | Medicine | Outstanding Scientist Award

The Fourth Hospital of Hebei Medical University | China

Qun Zhao is a distinguished medical professional affiliated with the Third Department of Surgery at the Fourth Hospital of Hebei Medical University. With extensive experience in surgical oncology, he has contributed significantly to the advancement of gastric and gastrointestinal cancer treatments. As a committed researcher and clinician, Dr. Zhao is an active member of multiple professional committees, driving innovation and excellence in cancer therapy.

Profile👤

ORCID

Strengths for the Awards

✅ Extensive Leadership in Oncology Research: Qun Zhao holds key positions in multiple national committees related to gastric cancer, gastrointestinal mesenchymal tumors, peritoneal tumors, tumor support therapy, and surgical nutrition. These roles highlight significant contributions to cancer research and treatment.

✅ Institutional and Professional Affiliations: Being part of the Fourth Hospital of Hebei Medical University, a reputed institution, strengthens credibility. His involvement in China’s Anti-Cancer Association further establishes his expertise in the field.

✅ Contributions to Cancer Surgery & Nutrition: Given the focus on gastric and peritoneal tumors, surgical oncology, and nutrition, Qun Zhao’s work aligns with impactful research that directly benefits patients and advances medical science.

✅ Editorial and Research Contributions: While specific journal publications, patents, or citation indices are not provided, editorial appointments and professional memberships suggest recognition by the academic community.

✅ Potential for Industry Impact: If consultancy or industry projects exist (to be detailed), they could indicate translational research, bridging academia with practical medical applications.

Education 🎓

Dr. Qun Zhao completed his medical education and specialized training in surgical oncology at renowned institutions. His academic journey has been marked by a commitment to continuous learning and specialization in gastrointestinal malignancies and surgical techniques.

Experience 🌟

Dr. Zhao holds a prominent position in the medical field, serving in various leadership roles, including the Standing Committee memberships in multiple prestigious oncology and surgical nutrition groups. His expertise extends across peritoneal tumor management, gastric cancer treatment, and gastrointestinal mesenchymal tumors. His clinical acumen and research contributions have had a significant impact on cancer treatment methodologies.

Research Interests On Medicine 🔬

Dr. Zhao’s research focuses on innovative surgical techniques, tumor nutrition, and multimodal cancer treatment strategies. His work aims to improve patient outcomes through targeted therapies and advanced surgical interventions. His ongoing projects include groundbreaking research in peritoneal metastases and gastrointestinal stromal tumors.

Awards 🏆

Dr. Zhao has been recognized for his outstanding contributions to surgical oncology and cancer research. His accolades include awards from national and international oncology societies for his pioneering work in gastric and peritoneal tumors.

Publications 📚

Dr. Zhao has authored numerous peer-reviewed articles in high-impact journals. Some of his key publications include:

  • Pioneering case: Robot-assisted remote radical distal gastrectomy for gastric cancer based on 5G communication technology
    • Authors: Honghai Guo, Yuan Tian, Jia Shi, Peigang Yang, Jiaxuan Yang, Pingan Ding, Xuefeng Zhao, Zhidong Zhang, Qun Zhao
    • Publication Year: 2024
    • DOI: 10.1016/j.isurg.2024.01.004
  • Comment on ‘Hand grip strength‐based cachexia index as a predictor of cancer cachexia and prognosis in patients with cancer’ by Xie et al.
    • Authors: Ping’an Ding, Jiaxiang Wu, Haotian Wu, Chenyu Sun, Muzi Meng, Scott Lowe, Yuan Tian, Honghai Guo, Lingjiao Meng, Qun Zhao
    • Publication Year: 2023
    • DOI: 10.1002/jcsm.13298
  • Comment on: ‘Triceps skinfold‐albumin index significantly predicts the prognosis of cancer cachexia: A multicentre cohort study’ by Yin et al.
    • Authors: Ping’an Ding, Haotian Wu, Jiaxiang Wu, Chenyu Sun, Muzi Meng, Peigang Yang, Yang Liu, Lingjiao Meng, Qun Zhao
    • Publication Year: 2023
    • DOI: 10.1002/jcsm.13304
  • Safety and efficacy of carbon nanoparticle suspension injection and indocyanine green tracer-guided lymph node dissection during robotic distal gastrectomy in patients with gastric cancer
    • Authors: Yuan Tian, Yecheng Lin, Honghai Guo, Yiyang Hu, Yong Li, Liqiao Fan, Xuefeng Zhao, Dong Wang, Bibo Tan, Qun Zhao
    • Publication Year: 2022
    • DOI: 10.1007/s00464-021-08630-8
  • Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
    • Authors: Yuan Tian, Qun Zhao, Yong Li, Liqiao Fan, Zhidong Zhang, Xuefeng Zhao, Bibo Tan, Dong Wang, Peigang Yang, Nicola Silvestris
    • Publication Year: 2021
    • DOI: 10.1155/2021/5590626

Conclusion 🥇

Dr. Qun Zhao’s dedication to oncology research and patient care continues to influence the medical community. His innovative approaches in surgery and therapeutic nutrition play a pivotal role in advancing cancer treatment. His contributions, both in research and clinical practice, underscore his commitment to improving healthcare outcomes globally.

Guoli Li | Medicine | Best Researcher Award

Published on by Forensic Scientist Awards

Dr. Guoli Li | Medicine | Best Researcher Award

Researcher | Hunan Provincial People’s Hospital (The First-Affiliated Hospital of Hunan Normal University) | China

Dr. Guoli Li, Ph.D., is an Assistant Professor at Hunan Provincial People’s Hospital and the First Affiliated Hospital of Hunan Normal University, located in Changsha, China. With expertise in Molecular Medicine, Cancer Research, and Nephrology, Dr. Li has contributed extensively to the scientific community, focusing on cutting-edge advancements in medical research.

Profile

Google Scholar

Strengths for the Awards

  • Extensive Research Background:
    Dr. Guoli Li has a strong academic and research foundation in molecular medicine, cancer research, and nephrology, with significant experience at reputable institutions like the University of Texas MD Anderson Cancer Center and Hunan Normal University.
  • Diverse Publication Record:
    Dr. Li has authored numerous high-impact publications in peer-reviewed journals such as Frontiers in Oncology, Genes and Diseases, and BMC Nephrology. These papers cover critical topics like cancer biomarkers, glomerulopathy, and ferroptosis in cancer, demonstrating expertise in innovative and clinically relevant research.
  • Bibliometric Contributions:
    Contributions to bibliometric studies (e.g., research on ferroptosis and mitophagy) highlight Dr. Li’s ability to analyze global research trends, adding to their scholarly influence.

Education 🎓

  • Ph.D. in Biochemistry and Molecular Biology (2013–2017)
    Central South University, Changsha, Hunan, China
  • B.S. in Biotechnology (2008–2012)
    Changchun University of Technology, Changchun, Jilin, China

Experience 💼

  • Research Scientist (09/2020–Present)
    Hunan Provincial People’s Hospital, Hunan Normal University, Changsha, Hunan, China
  • Postdoctoral Fellow (09/2018–08/2020)
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  • Instructor (06/2018–06/2020)
    Guangzhou Medical University, Guangzhou, Guangdong, China
  • Technician (08/2012–08/2013)
    Sansure Biotech Inc., Changsha, Hunan, China

Research Interests On Molecular Medicine🔬

Dr. Li’s research spans:

  • Molecular mechanisms in cancer biology 🧬
  • Nephrology, focusing on lupus nephritis and glomerulopathy 🩺
  • Biomarker identification and therapeutic development 🚑

Awards 🏆

  • 2018: Outstanding Graduate
  • 2016-2017: Excellent Graduate Student
  • 2009-2010: Excellent Student and Excellent Student Leader

Publications 📚

  • Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing
    Authors: G Li, X Guo, L Tang, M Chen, X Luo, L Peng, X Xu, S Wang, Z Xiao, W Yi, …
    Year: 2017
    Citations: 43
  • Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients
    Authors: G Li, X Guo, M Chen, L Tang, H Jiang, JX Day, Y Xie, L Peng, X Xu, J Li, …
    Year: 2018
    Citations: 39
  • What’s the difference between lung adenocarcinoma and lung squamous cell carcinoma? Evidence from a retrospective analysis in a cohort of Chinese patients
    Authors: W Wang, H Liu, G Li
    Year: 2022
    Citations: 26
  • Integrated analysis of promoter mutation, methylation and expression of AKT1 gene in Chinese breast cancer patients
    Authors: J Heng, X Guo, W Wu, Y Wang, G Li, M Chen, L Peng, S Wang, L Dai, …
    Year: 2017
    Citations: 20
  • The research landscape of ferroptosis in cancer: a bibliometric analysis
    Authors: G Li, Y Liang, H Yang, W Zhang, T Xie
    Year: 2022
    Citations: 17
  • Mutation screening of 10 cancer susceptibility genes in unselected breast cancer patients
    Authors: Y Xie, G Li, M Chen, X Guo, L Tang, X Luo, S Wang, W Yi, L Dai, J Wang
    Year: 2018
    Citations: 16
  • Hyperuricemia is an independent risk factor for renal pathological damage and poor prognosis in lupus nephritis patients
    Authors: T Xie, M Chen, X Tang, H Yin, X Wang, G Li, J Li, X Zuo, W Zhang
    Year: 2016
    Citations: 16
  • Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients
    Authors: H Deng, M Chen, X Guo, J Heng, X Xu, L Peng, H Jiang, G Li, JX Day, J Li, …
    Year: 2019
    Citations: 11
  • Bibliometric insights of global research landscape in mitophagy
    Authors: G Li, W Yin, Y Yang, H Yang, Y Chen, Y Liang, W Zhang, T Xie
    Year: 2022
    Citations: 10
  • LINC00467 is upregulated by DNA copy number amplification and hypomethylation and shows ceRNA potential in lung adenocarcinoma
    Authors: W Wang, H Bo, Y Liang, G Li
    Year: 2022
    Citations: 9

Conclusion 📝

Dr. Guoli Li is a passionate scientist and educator committed to advancing medical research and improving clinical outcomes. With numerous prestigious publications, awards, and invitations as a reviewer for reputed journals, Dr. Li continues to contribute profoundly to the global research community. 🌐